Introduction {#sec1}
============

Tumour necrosis factor α (TNF-α) plays a major role in the progression of joint destruction and proliferation of synoviocytes in rheumatoid arthritis (RA) \[[@cit0001]\]. Therapies neutralising TNF-α have greatly improved the treatment outcomes in RA \[[@cit0002]\]. Unfortunately, some RA patients do not respond to anti-TNF-α treatment, and in some patients positive responses cannot be maintained, suggesting that there are alternative drivers of RA pathogenesis \[[@cit0003]\]. Binding of antibodies to transmembrane TNF-α on target cells seems to be crucial for inducing complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and reverse signalling. However, these processes alone do not fully explain the mechanism of responses to anti-TNF-α therapy \[[@cit0004]\].

Curiously, treatment with TNF-α inhibitors does not significantly affect circulating TNF-α levels \[[@cit0005]\] and does not modulate the expression of TNF-α in the synovial tissue \[[@cit0006]\]. Therefore, there may exist alternative drivers of RA pathogenesis, which are affected by TNF-α inhibitors through as yet unidentified mechanisms \[[@cit0004]\].

The discovery that interleukin-17 (IL-17) is involved in autoimmune disease has created a new concept of the RA pathogenesis of RA \[[@cit0001]\]. Animal studies have shown there exists an association between IL-17 signalling and joint inflammation \[[@cit0007], [@cit0008]\]. IL-17 is derived largely from Th17 lymphocytes that differentiate from naive CD4^+^ T cells in response to a particular combination of inflammatory cytokines. It has been demonstrated that IL-23 is essential for Th17 differentiation \[[@cit0009]\], acting together with IL-6, IL-1β, IL-21, and TGF-β \[[@cit0010]\]. Interestingly, TNF-α does not seem to be directly involved in this process \[[@cit0011]\]. In addition to IL-17, activated Th17 cells produce several proinflammatory cytokines and chemokines, including CC-chemokine ligand 20 (CCL20), which acts as a chemoattractant for Th17 cells. Thus, an increased production of IL-17 and CCL20 may result in a positive feedback loop leading to self-perpetuating chronic inflammation \[[@cit0009]\].

The exact role of IL-17 in RA is not fully understood \[[@cit0009]\]; it has been suggested that the mechanisms driving inflammation in RA could be different in different patients \[[@cit0012], [@cit0013]\]. A correlation between serum levels of IL-17 (and of related molecules IL-23 and CCL20) and the disease activity has been observed in some studies \[[@cit0014]-[@cit0017]\] but not in others \[[@cit0018], [@cit0019]\]. Moreover, it is unclear whether and how IL-17 impacts the effectiveness of anti-TNF-α treatment. Such an effect is possible because IL-17 has been demonstrated in many models to synergise with TNF-α to amplify the production of pro-inflammatory cytokines, including CCL20 \[[@cit0017]\]. Some studies have reported serum IL-17 and CCL20 clearly decreasing after anti-TNF-α treatment \[[@cit0017]\]. Other studies did not detect such an effect \[[@cit0018], [@cit0019]\] or found an increase in serum IL-17, even in patients with clinical improvement following the treatment \[[@cit0020]\].

Interestingly, the blockade of IL-17 signalling in RA does not always result in a desired clinical effect \[[@cit0021]\]. A recent meta-analysis has established that brodalumab, an IL-17R-antagonist, was not as effective as a placebo in RA \[[@cit0022]\]. Similarly, secukinumab, an anti-IL17 antibody, offered no-to-little improvement in RA. It has been suggested that the role of IL-17 in RA may depend on the stage of the disease \[[@cit0009]\]. Synovial fluid in early RA contains significantly elevated levels of IL-17 when compared with the synovial fluid from patients with long-lasting disease \[[@cit0023]\].

The aim of the present study was to investigate if serum levels of IL-17, CCL20, and/or IL-23 reflect the disease activity and response to anti-TNF-α therapy in patients with RA.

Material and methods {#sec2}
====================

Patients {#sec2.1}
--------

The study was performed prospectively on 22 consecutive Caucasian RA patients, qualified to initiate anti-TNF-α treatment, according to American-European Consensus Group classification criteria \[[@cit0024]\]. The patients were evaluated before and after 12 weeks of therapy. The study was approved by the Poznan University of Medical Sciences Bioethics Committee (No. 1067/15), and all patients gave their informed consent.

Disease activity {#sec2.2}
----------------

Disease activity was assessed by the 28-joint disease activity score (DAS28) \[[@cit0025]\]. It is calculated from the number of tender (TEN28) and swollen (SW28) joints, erythrocyte sedimentation rate (ESR), and the disease assessment by the patient (VAS), according to the formula: DAS 28 = 0.56 √ (TEN28) + 0.28 √ (SW28) + 0.70 Ln (ESR) + 0.014 (VAS) \[[@cit0025]\]. The therapeutic response was evaluated after 12 weeks of therapy according to the European League Against Rheumatism (EULAR) response criteria \[[@cit0026]\].

Laboratory analysis {#sec2.3}
-------------------

Samples of serum were collected by routine methods at the time of clinical examination in a fasting state. Serum was aliquoted and stored at --70°C until assayed in batch. Serum concentrations of IL-17, CCL20, and IL-23 were measured with specific immunoassays (R&D Systems, USA), as per manufacturer's instructions. Estimated detection levels were 0.01 pg/ml and 0.47 pg/ml, and 16.3 pg/ml for IL-17, CCL20, and IL-23, respectively. Values below the detection limit were assigned a value of zero. All other laboratory tests were performed routinely by the hospital central laboratory.

Statistical analysis {#sec2.4}
--------------------

Statistical analyses were performed with Statistica 10.0 software (StatSoft Polska, Krakow, Poland). Normality of the data distribution was tested with the Shapiro-Wilk's test. The data are presented as medians and interquartile ranges or means and standard deviations or percentage, as appropriate. The Wilcoxon test was used to compare parameters before and after treatment. Differences between unpaired data were analysed with the Mann-Whitney test. Correlation between variables was analysed with the Spearman's rank correlation coefficient. The differences were considered significant at *p* \< 0.05.

Results {#sec3}
=======

Twenty-two patients with RA qualified to receive anti-TNF-α treatment were enrolled and analysed. All patients had previously been treated with (at least) two synthetic disease-modifying anti-rheumatic drugs (methotrexate, leflunomide, sulfasalazine, or cyclosporine) with no satisfactory effects. All patients had an active disease (DAS-28 \> 5.1) and received anti-TNF-α treatment according to standard protocols. Eleven patients (50%) received simultaneously methotrexate (the remaining patients did not tolerate methotrexate). Corticosteroids (≤ 5 mg prednisone/day) and non-steroid anti-inflammatory drugs (NSAIDs) were allowed but were given at stable doses for at least four weeks before and during anti-TNF-α therapy. Full clinical and demographic patient characteristics at baseline are presented in [Table 1](#t0001){ref-type="table"}.

###### 

Patients' baseline characteristics

  -----------------------------------------------------------
  Demographic and clinical features   
  ----------------------------------- -----------------------
  Age (years)                         52.8 ±12.4

  Men (%)                             3 (14)

  Disease duration (years)            10.3 ±6.7

  Rheumatoid factor, presence (%)     18 (82)

  BMI (kg/m^2^)                       24.2 ±4.5

  Current smoking (%)                 4 (18)

  Other diseases (%)                  Diabetes: 1 (4)\
                                      Hypertension: 8 (36)

  **Treatment**                       

  Prednisone (\< 5 mg/24 h) (%)       12 (54)

  NSAIDS (%)                          17 (77)

  Methotrexate (%)                    11 (50)

  Anti-TNF-α treatment (%)            adalimumab: 5 (23)\
                                      certolizumab: 9 (41)\
                                      etanercept: 2 (9)\
                                      golimumab: 2 (9)\
                                      infliximab: 4 (18)
  -----------------------------------------------------------

Data presented as the mean ±SD or %

Twelve weeks of biologic treatment resulted in a significant improvement in the majority of the patients, with only two patients (9%) identified as EULAR non-responders. The favourable response to therapy was reflected both by clinical and standard biochemical criteria ([Table 2](#t0002){ref-type="table"}).

###### 

Selected parameters before and after treatment

                                   Before treatment (*n* = 22)   After 12-weeks of treatment (*n* = 22)   *p*-value (Wilcoxon test)
  -------------------------------- ----------------------------- ---------------------------------------- ---------------------------
  DAS28 (ESR)                      5.34 (5.18-6.08)              3.56 (3.15-3.99)                         \< 0.001
  TEN28                            10.0 (8.0-12.0)               2.0 (1.0-3.0)                            \< 0.001
  SW28                             6.0 (4.0-9.0)                 1.5 (0.0-4.0)                            \< 0.001
  VAS (mm)                         70 (60-82)                    41 (30-50)                               \< 0.001
  ESR (mm/h)                       22 (10-30)                    15 (8-25)                                0.012
  CRP (mg/l)                       6.80 (2.30-15.80)             2.15 (0.10-5.50)                         0.021
  Leukocytes (10^3^/µl)            8.8 (7.2-9.9)                 7.8 (6.6-9.6)                            0.022
  Neutrophils (10^3^/µl)           5.4 (3.6-7.1)                 4.7 (3.3-5.8)                            0.006
  Lymphocytes (10^3^/µl)           2.0 (1.6-2.6)                 2.2 (1.7-3.1)                            0.079
  Neutrophil-to-lymphocyte ratio   2.3 (1.8-3.8)                 1.7 (1.3-2.7)                            0.024
  Erythrocytes (10^6^/µl)          4.5 (4.3-4.7)                 4.5 (4.3-4.6)                            0.357
  Haemoglobin (g/dl)               12.5 (11.9-13.6)              12.3 (12.1-13.5)                         0.765
  Platelets (10^3^/µl)             299 (268-319)                 272 (259-309)                            0.044

Data presented as the median (interquartile range)

DAS28 -- 28-joint disease activity score; TEN28 -- the number of tender joints; SW -- the number of swollen joints; VAS -- subjective disease activity assessment on the visual analogue scale; ESR -- erythrocyte sedimentation rate; CRP -- C-reactive protein

Serum concentrations of IL-17A and CCL20 did not change significantly over the course of therapy (\[median and IQR\] IL-17: 0.00 \[0.00-3.31\] vs. 0.17 \[0.00-4.45\] pg/ml and CCL20: 22.0 \[17.0-26.0\] vs. 22.5 \[19.0-31.0\] pg/ml) ([Figs. 1](#f0001){ref-type="fig"}, [2](#f0002){ref-type="fig"}). Serum IL-23 levels were below the detection limit both before and after the treatment.

![Individual changes in serum IL-17A during anti-TNF-α therapy in rheumatoid arthritis patients](CEJI-43-80045-g001){#f0001}
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Also, the pattern of changes in serum IL-17 and CCL20 over the course of therapy showed no correlation with changes in standard inflammatory parameters (leukocytes, CRP and ESR) and disease activity (DAS28, SW28, TEN28, VAS). These patterns did not seem to be different in patients who did not respond to therapy. There was also no apparent association between the magnitude of serum IL-17 or CCL20 and the type of anti-TNF-α agent used, or between the simultaneous treatment with corticosteroids and NSAIDs).

Discussion {#sec4}
==========

The main observation of the present study is that the mean serum concentrations of IL-17 and CCL20 did not change significantly over the course of anti-TNF-α therapy and did not parallel changes in the clinical disease activity and standard biochemical parameters.

Such associations were absent also in other studies \[[@cit0018], [@cit0019]\] and included no correlation between serum IL-17 radiologic features of RA and no changes following the treatment \[[@cit0018], [@cit0019]\]. However, other studies detected a correlation between serum IL-17 and CCL20 and the disease activity and the response to biologic therapy \[[@cit0014]-[@cit0017]\].

We also tried to evaluate whether baseline serum levels of IL-17 and CCL20 could be prognostic markers for predicting therapeutic response to biologic therapy in RA. Our data show that the measurement of serum IL-17 and CCL20 does not provide additional information that would help to predict the response to treatment more accurately. Since, however, only two patients did not respond to treatment, it is difficult to draw final conclusions in this respect. Earlier studies did not identify IL-17 as a predictor of successful response to therapy with either anti TNF-α \[[@cit0027]\] or anti-IL-6R \[[@cit0027], [@cit0028]\]. On the other hand, Yue *et al.* demonstrated that high baseline levels of circulating Th17 cells were negative predictors of the effect of anti-TNF-α therapy \[[@cit0029]\]. And accordingly, high baseline levels ofIL-17were also shown to predict poor therapeutic response to anti-TNF treatment \[[@cit0013]\]. Here, we detect no predictive value of IL-17 or (for the first time) Th17-attracting chemokine CCL20.

The lack of any apparent associations of IL-17 in our study could be related the long course of the disease in the patient group analysed. Although Th17 cells in peripheral blood are relatively more frequent in patients with early RA \[[@cit0029]\], such an observation was absent in later stages of RA \[[@cit0030]\]. In addition, Th17 cells are found only rarely in joints of patients with long-lasting inflammation \[[@cit0009]\]. Also, IL-17 in the synovial fluid appears to be elevated in early -- but not in late-stage RA \[[@cit0023]\]. Moreover, the frequency of Th17 cells and serum IL-17 levels did not correlate with the disease activity (DAS28) in long-lasting RA \[[@cit0018], [@cit0030]\].

Animal studies suggested the existence of both IL-23/IL-17-dependent and IL-23/IL-17-independent stages of arthritis \[[@cit0031]\] and showed a limited time window for anti-IL-17 treatment to be effective in chronic arthritis \[[@cit0009]\].

It has also been suggested that different members of the IL-17 cytokine family play roles at different stages of RA. In this respect IL-17(A) is thought to be an inducer of inflammation, while IL-17F is implicated in chronic inflammation \[[@cit0032], [@cit0033]\]. Accordingly, the blockade of IL-17A in long-lasting RA has been shown to be of less clinical benefit than in early disease \[[@cit0034]\].

Our results might have been affected also by naturally low levels of IL-17 in serum \[[@cit0032]\]. If fact, serum IL-17 levels in some patients were undetectable despite the use of high sensitivity tests. An explanation may be that inflammation in these patients was not driven by the IL-17 pathway. In this respect, it has been observed that non-responders to anti-TNF-α produce high levels of IL-23/IL-17 and have a high frequency of circulating Th17 cells \[[@cit0012]\]. High baseline levels of IL-17 were also identified as a significant predictor of poor therapeutic response to anti-TNF treatment \[[@cit0013]\]. Because our group of patients consisted mainly of successful responders to anti-TNF-α, the IL-23/IL-17 pathway may have not been involved.

We also detected no effect of anti-TNF-α therapy on serum CCL20. Previous studies suggested that serum CCL20 in RA decreases in response to biologic treatment \[[@cit0017]\]. It has also been suggested that a polymorphism in CCR6, the gene encoding a receptor for CCL20 on Th17 cells, may determine the recruitment of Th17 cell to the joints, systemic IL-17, and RA susceptibility \[[@cit0035]\].

Despite lack of changes of serum levels of IL-17 and CCL20 in RA patients upon anti-TNF-α therapy in our study, it is possible that anti-TNF-α inhibitors could affect IL-17/CCL20 triggered signalling in effector cells \[[@cit0036]\]. This may result in an effect on disease activity \[[@cit0037]\]. It was suggested that the early responses to anti-TNF-α treatment in psoriasis may be due to decreased tissue responsiveness to IL-17 due to suppressed IL-17 receptor expression in keratinocytes \[[@cit0038]\]. It has also been shown that the increased IL-17 production in RA patients after anti-TNF treatment was accompanied by a decrease in Th17-specific CC-chemokine receptor expression, which might prevent homing of these potentially pro-inflammatory cells to the synovium \[[@cit0039]\]. It is therefore possible that despite the lack of changes of serum levels of IL-17 and CCL20, the downregulation of IL-17/CCL20 receptors affect IL-17/CCL20 triggered signalling during treatment with TNF-α inhibitors.

Our study has some limitations, including a single-centre design and a small sample size. Additionally, patients had received a wide variety of medications.

Conclusions {#sec5}
===========

Serum levels of IL-17A and CCL20 did not parallel changes in the clinical status and standard biochemical parameters that occur in patients undergoing anti-TNF-α treatment for RA. However, it is possible that anti-TNF-α inhibitors could affect IL-17/CCL20 triggered signalling in effector cells. Finally, the measurement of IL-17A and CCL20 in serum does not seem to provide additional information that would help to predict or monitor the response to biologic treatment in RA.
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